|
H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies. |
|
|
Stock and Other Ownership Interests - ARIAD |
Consulting or Advisory Role - Akebia Therapeutics; Amgen; Celgene; H3 Biomedicine; Janssen Oncology; Novartis; Pfizer; Takeda |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen; Daiichi Sankyo; FORMA Therapeutics; Genentech; H3 Biomedicine; Janssen; Seagen |
|
|
Research Funding - H3 Biomedicine |
|
|
Research Funding - Celgene; H3 Biomedicine; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - H3 Biomedicine |
Consulting or Advisory Role - H3 Biomedicine |
Research Funding - H3 Biomedicine |
|
|
Stock and Other Ownership Interests - Abbvie |
Consulting or Advisory Role - Celgene; Novartis |
Speakers' Bureau - Alexion Pharmaceuticals; Novartis |
Research Funding - Boehringer Ingelheim (Inst); Celgene (Inst); Eleos (Inst); GlaxoSmithKline (Inst); Incyte (Inst) |
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Celgene; Incyte; Novartis |
|
|
No Relationships to Disclose |
|
|
Employment - Agenus; H3 Biomedicine |
Stock and Other Ownership Interests - Agenus |
Research Funding - ArQule |
|
|
Employment - H3 Biomedicine |
|
|
Employment - H3 Biomedicine |
|
|
Employment - Eisai; H3 Biomedicine |
|
|
Employment - H3 Biomedicine |
|
|
Employment - H3 Biomedicine |
|
|
Employment - H3 Biomedicine |
|
|
Employment - Boehringer Ingelheim; H3 Biomedicine, Eisai; Novartis (I) |
Stock and Other Ownership Interests - Novartis, Celgene |
|
|
Employment - H3 Biomedicine |
Stock and Other Ownership Interests - H3 Biomedicine |
|
|
No Relationships to Disclose |